Minor
Agni-01 · OBX-115 in Advanced Solid Tumors
Enrollment increased: 208 → 254 participants
Obsidian Therapeutics, Inc.Phase 1/2 NCT06060613 Registry history of NCT06060613 on ClinicalTrials.gov (opens the registry)
1 trial changed in the last 30 days: 0 stopped, 0 with notable changes, 1 with a minor change only.
Enrollment increased: 208 → 254 participants
Obsidian Therapeutics, Inc.Phase 1/2 NCT06060613 Registry history of NCT06060613 on ClinicalTrials.gov (opens the registry)
| Phase 1/2 | 1 |
Lung Cancer (1) · Melanoma (1) · Non-Small Cell Lung Cancer (NSCLC) (1)